Antenatal corticosteroid therapy (ACT) and size at birth: A population-based analysis using the Finnish Medical Birth Register

Abstract

Background Antenatal corticosteroid therapy (ACT) is used clinically to prepare the fetal lung for impending preterm birth, but animal and human studies link corticosteroids to smaller birth size. Whether ACT is associated with birth size is debated; therefore, we assessed differences in birth size in treated versus untreated pregnancies. Methods and findings This observational register-based study used data from the Finnish Medical Birth Register (FMBR) covering all births in Finland (January 1, 2006–December 31, 2010). We used unadjusted and adjusted regression analyses as well as propensity score matching (PSM) to analyze whether birth size differed by ACT exposure. PSM provides a stringent comparison, as subsamples were created matched on baseline and medical characteristics between treated and untreated women. All analyses were stratified by timing of birth. The primary study outcome was birth size: birth weight (BWT), birth length (BL), ponderal index (PI), and head circumference (HC) measured immediately after birth and recorded in the FMBR. Additional analyses explored indicators of neonatal health in relation to ACT exposure and birth size. A total of 278,508 live-born singleton births with ≥24 gestational completed weeks were registered in the FMBR during the 5-year study period. Over 4% of infants were born preterm, and 4,887 women were treated with ACT (1.75%). More than 44% of the exposed infants ( n = 2,173) were born at term. First, results of unadjusted regression analyses using the entire sample showed the greatest reductions in BWT as compared to the other analytic methods: very preterm −61.26 g (±SE 24.12, P < 0.01), preterm −232.90 g (±SE 17.24, P < .001), near term −171.50 g (±SE 17.52, P < .001), and at term −101.95 g (±SE 10.89, P < .001). Second, using the entire sample, regression analyses adjusted for baseline and medical conditions showed significant differences in BWT between exposed and unexposed infants: very preterm −61.54 g (±SE 28.62, P < .03), preterm −222.78 g (±SE 19.64, P < .001), near term −159.25 g (±SE 19.14, P < .001), and at term −91.62 g (±SE 11.86, P < .03). Third, using the stringent PSM analyses based on matched subsamples, infants exposed to ACT weighed less at birth: −220.18 g (±SE 21.43, P < .001), −140.68 g (±SE 23.09, P < .001), and −89.38 g (±SE 14.16, P < .001), born preterm, near term, and at term, respectively. Similarly, significant reductions in BL and HC were also observed using the three analytic methods. There were no differences among postterm infants regardless of analytic method. Likewise, we observed no differences with respect to PI. Additional analyses showed that exposed and unexpo...

Does Antenatal Betamethasone Alter White Matter Brain Development in Growth Restricted Fetal Sheep?

“…Single and repeat courses of antenatal glucocorticoids reduce body weight in fetal sheep (Sloboda et al, 2000;Miller et al, 2007Miller et al, , 2012, with a dose-dependent effect (Ikegami et al, 1997). A large population-based Finnish study confirms that birth weight is significantly reduced in infants exposed to antenatal steroids in infants born preterm, near-term or at term (Rodriguez et al, 2019). This study did not stratify for infants with FGR, but noted that 44% of their glucocorticoid-exposed infants were born at term and therefore unnecessarily received steroids.…”

Antenatal corticosteroids: a reappraisal of the drug formulation and dose

“…26 A poorly documented number of women have threatened preterm labor and are given ACS and deliver at term with some clinical data suggesting adverse effects on fetal growth and neurodevelopmental outcomes. 21,37,41 There is also no RCT data showing benefits for periviable deliveries prior to 24 weeks. 19 Therefore, our approximate estimate is that 40-50% of all deliveries in the US may receive ACS which benefit only a minority of the pregnancies with a dose of ACS that is the wrong drug at too high a dose.…”

Cellular senescence mediates the detrimental effect of prenatal dexamethasone exposure on postnatal long bone growth in mice offspring

“…Prenatal corticosteroid use in clinic has been shown to be effective in accelerating lung maturation and reducing the incidence of respiratory complications in infant [1]. However, clinical studies provide evidence that these short-term bene ts are associated with reduction in birth size for infants born preterm, near term, or at term [2], and suppression of fetal bone turnover in infants at birth [3]. In addition, clinical trial data show that lower birth weight is associated with lower peak bone mass in adult offspring [4,5].…”